Venetoclax (Venclexta/Venclyxto) + Azacitidine

Type: drug combination

Status: FDA Approved

Developer: AbbVie and Genentech (Roche)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026